DR. ERIC J. AVERY M.D. NPI 1093934598

NPI Details

DR. Eric J. Avery, M.D. is a hematology and oncology internal medicine in Lincoln, NE with 20 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. DR. Eric J. Avery, M.D. NPI is 1093934598. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: UNIVERSITY OF NEBRASKA COLLEGE OF MEDICINE
Graduation Year:2006

The provider's business location address is:

4004 PIONEER WOODS DR
LINCOLN, NE
ZIP 68506-548
Phone: (402) 484-4900
Fax: (402) 484-6456

The NPI 1093934598 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferric carboxymaltose, 1 mg (HCPCS:J1439)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg (HCPCS:J1569)
• Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units (HCPCS:Q5106)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, rituximab-abbs, biosimilar, (truxima), 10 mg (HCPCS:Q5115)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, atropine sulfate, 0.01 mg (HCPCS:J0461)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Uric acid level, blood (HCPCS:84550)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, irinotecan, 20 mg (HCPCS:J9206)
• Injection, pegfilgrastim-bmez, biosimilar, (ziextenzo), 0.5 mg (HCPCS:Q5120)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Injection, potassium chloride, per 2 meq (HCPCS:J3480)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Cyclophosphamide, 100 mg (HCPCS:J9070)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Injection, cisplatin, powder or solution, 10 mg (HCPCS:J9060)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Injection, doxorubicin hydrochloride, 10 mg (HCPCS:J9000)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Thyroxine (thyroid chemical), free (HCPCS:84439)
• Ferritin (blood protein) level (HCPCS:82728)
• Magnesium level (HCPCS:83735)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Creatine kinase (cardiac enzyme) level, total (HCPCS:82550)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Application of on-body injector for under skin injection (HCPCS:96377)
• Follow-up hospital inpatient care per day, typically 15 minutes (HCPCS:99231)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Blood test, clotting time (HCPCS:85610)
• Chemical receptor analysis (HCPCS:84238)
• Blood test, basic group of blood chemicals (calcium, total) (HCPCS:80048)
• Injection of drug or substance into vein (HCPCS:96374)
• Red blood count, automated test (HCPCS:85045)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
• Administration of prolonged chemotherapy into vein (HCPCS:96416)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Initial hospital inpatient care per day, typically 50 minutes (HCPCS:99222)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 125 (HCPCS:86304)
• Initial hospital inpatient care per day, typically 30 minutes (HCPCS:99221)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Established patient office or other outpatient visit, 10-19 minutes (HCPCS:99212)
• Cortisol (hormone) measurement, total (HCPCS:82533)
• Manual urinalysis test with examination using microscope, non-automated (HCPCS:81000)
• Amylase (enzyme) level (HCPCS:82150)
• Vitamin d-3 level (HCPCS:82306)
• Lipase (fat enzyme) level (HCPCS:83690)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• New patient office or other outpatient visit, 30-44 minutes (HCPCS:99203)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Phosphate level (HCPCS:84100)
• Biopsy and aspiration of bone marrow sample for diagnosis (HCPCS:38222)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional (HCPCS:99211)
• Administration of influenza virus vaccine (HCPCS:G0008)
• Folic acid level, serum (HCPCS:82746)
• Influenza vaccine, quadrivalent derived from cell cultures, preservative and antibiotic free (HCPCS:90674)

The enumeration date for this NPI number is 4/24/2007 and was last updated on 2/25/2021.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: